CSI Market
Sign In | Register

Alexion Pharmaceuticals Inc (ALXN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ALXN Annual Cash Flow →
Reviewing cash flow figures over time highlights how Alexion Pharmaceuticals Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2021)
3 Months 		(Dec 31 2020) (Sep 30 2020) (Jun 30 2020) (Mar 31 2020)
Operating Activities
Income489.20
Depreciation & amortization75.60
Amortization of Other Assets5.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability9.20
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-59.50
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment-25.30
Share-based Compensation76.60
Income from affiliates0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total10.90
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability-
Investment Income Net Amortization Of Discount And Premium-
Payment For Contingent Consideration Liability Operating Activities-
Gain Loss On Derivative Instruments Net Pretax-19.30
Gain Loss On Purchase Options-
Consolidation Of Noncontrolling Interest Including Noncash Expense For Acquired Assets210.20
Income taxes52.90
Unrealized Gain (Loss) on Investments9.60
Increase (Decrease) in Accounts Receivable-87.90
Increase (Decrease) in Accounts Payable and Accrued Liabilities-118.40
Accrued liabilities0.00
Deferred revenue0.00
Increase (Decrease) in Prepaid Expense and Other Assets11.00
Other Working Capital0.00
Other Noncash Income (Expense)2.80
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.00
Discontinued operations0.00
Net Cash flow from Operating Activities637.60
Investing Activities
Capital Expenditures-130.20
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities3.30
Payments to Acquire Trading Securities Held-for-investment-7.00
Proceeds from other investments0.00
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Payments to Acquire Other Investments0.00
Purchases of non-current assets0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Investment in affiliate0.00
Sale of businesses0.00
Proceeds from sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-133.90
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-32.60
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock15.20
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.00
Other net-8.20
Payment Of Taxes In Exchange Of Treasury Stock-
Payment for Contingent Consideration-
Payments for Contingent Consideration-
Proceeds from Grants-
Noncash Or Part Noncash Acquisition Contingent Consideration Issued-
Other Significant Noncash Transaction Value Of Consideration Given-
Operating Right Of Use Assets Exchanged For Operating Lease Liability1.50
Capital Expenditures Incurred But Not Yet Paid5.40
Dividends paid to minority interests0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-18.70
Effect of exchange rate on cash flow-13.10
Discontinued operations0.00
Free Cash Flow507.40
Total Cash Flow471.90
4 historic quarters locked

Sign in to unlock the full Alexion Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About ALXN Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.